This study tests a new drug combination (ONC-392 plus lutetium) in people with a type of advanced prostate cancer that has stopped responding to standard hormone therapy. About 148 participants will be randomly assigned to receive the combination or an active control. The goal is…
Phase: PHASE1, PHASE2 • Sponsor: OncoC4, Inc. • Aim: Disease control
Last updated Apr 29, 2026 15:01 UTC